Please ensure Javascript is enabled for purposes of website accessibility

What's Going on With COVID Booster Shots?

By Keith Speights and Brian Orelli, PhD - May 8, 2021 at 7:01AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Here are the latest updates for the key COVID-19 vaccine makers.

Millions of Americans have already been fully vaccinated against COVID-19. However, there's a real possibility that another booster shot could be needed. In this Motley Fool Live video recorded on April 21, 2021, Motley Fool contributors Keith Speights and Brian Orelli answer a viewer's question about what's going on with these booster vaccines.

Keith Speights: Elizabeth has a question. She asks, are there any updates on the development of the Pfizer (PFE -1.40%) and/or Moderna (MRNA -5.06%) booster shots that are projected to be possibly needed in the near future?

Brian Orelli: Yeah. I think they're in clinical trials, is that right?

Speights: Yes. They're taking a little bit different approach. Pfizer is in clinical studies with literally just a third booster shot of their existing vaccine, and Moderna though, they're testing of variant specific shot.

Orelli: Right and I think Novavax (NVAX -5.56%) is at least developing a variant specific shot although I haven't seen that they are in clinical trials yet.

Speights: Pfizer had talked about also pursuing a variants specific shot but I haven't seen anything yet anyway that led me to believe that they are in clinical testing with that at this point. That's where we are.

I think Moderna CEO said that the company expects to have a booster shot available by the fall, or certainly before the end of the year, and I think you've said by the fall.

Orelli: Yes. I think the thing here is probably they're just going to look at antibody levels. They're not going to try to measure the efficacy based on placebo-controlled clinical trial where they would look for whether you'd get COVID-19, and so that allows them to your smaller trials and also allows them to get the data a lot quicker than having to actually measure efficacy in the development of COVID the disease.

Brian Orelli, PhD owns shares of Novavax. Keith Speights owns shares of Pfizer. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$48.58 (-1.40%) $0.69
Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$37.18 (-5.56%) $-2.19
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$150.00 (-5.06%) $-8.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
394%
 
S&P 500 Returns
127%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.